These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26761969)

  • 1. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
    Im SI; Jeong DS; Park SJ; Park KM; Huh J; Kim JS; On YK
    Int J Cardiol; 2015; 186():213-5. PubMed ID: 25828118
    [No Abstract]   [Full Text] [Related]  

  • 4. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New ral nticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin S; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015 Aug; 55(8):30-34. PubMed ID: 28294916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
    Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
    Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
    Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
    Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.
    Shah RR; Pillai A; Schafer P; Meggo D; McElderry T; Plumb V; Yamada T; Kumar V; Doppalapudi H; Gunter A; Pentecost E; Maddox WR
    Am J Cardiol; 2017 Aug; 120(3):404-407. PubMed ID: 28595862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
    Beyer-Westendorf J; Ehlken B; Evers T
    Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.
    Brendel LC; Dobler F; Hessling G; Michel J; Braun SL; Steinsiek AL; Groha P; Eckl R; Deisenhofer I; Hyseni A; Roest M; Ott I; Steppich B
    J Interv Card Electrophysiol; 2017 Sep; 49(3):237-244. PubMed ID: 28735423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
    Jackevicius CA; Tsadok MA; Essebag V; Atzema C; Eisenberg MJ; Tu JV; Lu L; Rahme E; Ho PM; Turakhia M; Humphries KH; Behlouli H; Zhou L; Pilote L
    Heart; 2017 Sep; 103(17):1331-1338. PubMed ID: 28286333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation: Uninterrupted oral anticoagulation in patients undergoing catheter ablation.
    Mearns BM
    Nat Rev Cardiol; 2015 Jul; 12(7):381. PubMed ID: 26031699
    [No Abstract]   [Full Text] [Related]  

  • 18. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
    Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
    J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.